Villard L, Bonino M C, Abidi F, Ragusa A, Belougne J, Lossi A M, Seaver L, Bonnefont J P, Romano C, Fichera M, Lacombe D, Hanauer A, Philip N, Schwartz C, Fontés M
INSERM U491, Faculté de Médecine La Timone, Université de la Méditerranée, Marseille, France.
J Med Genet. 1999 Mar;36(3):183-6.
We report on the evaluation of a strategy for screening for XNP/ATR-X mutations in males with mental retardation and associated dysmorphology. Because nearly half of the mutations in this gene reported to date fall into a short 300 bp region of the transcript, we decided to focus in this region and to extend the mutation analysis to cases with a negative family history. This study includes 21 mentally retarded male patients selected because they had severe mental retardation and a typical facial appearance. The presence of haemoglobin H or urogenital abnormalities was not considered critical for inclusion in this study. We have identified six mutations which represents a mutation detection rate of 28%. This figure is high enough for us to propose this strategy as a valid first level of screening in a selected subset of males with mental retardation. This approach is simple, does not require RNA preparation, does not involve time consuming mutation detection methods, and can thus be applied to a large number of patients at a low cost in any given laboratory.
我们报告了一项针对患有智力障碍及相关畸形的男性进行XNP/ATR-X突变筛查策略的评估。由于迄今为止报道的该基因近一半突变位于转录本一个短的300 bp区域内,我们决定聚焦于该区域,并将突变分析扩展至无家族病史的病例。本研究纳入了21名智力障碍男性患者,入选原因是他们患有严重智力障碍且面部外观典型。血红蛋白H或泌尿生殖系统异常的存在对于本研究的纳入并不关键。我们鉴定出六个突变,突变检出率为28%。这个数字足够高,使我们能够将此策略作为对特定男性智力障碍亚组进行有效一级筛查的方法。这种方法简单,无需制备RNA,不涉及耗时的突变检测方法,因此在任何给定实验室都能以低成本应用于大量患者。